American Society of Cataract and Refractive Surgery Meeting

BOSTON — In this Healio Video Perspective from the ASCRS meeting, Brett H. Mueller II, DO, PhD, ABO, discusses how adopting the EVO ICL into his practice has benefited him and his patients.

Catch up on the most popular videos from Eyecelerator@ASCRS as Healio’s coverage of the American Society of Cataract and Refractive Surgery meeting continues.

BOSTON — In this Healio Video Perspective from the ASCRS meeting, John Sheets, PhD, of Pantheon Vision previews a product designed to address unmet needs in corneal blindness compared with the standard of care of transplantation.

In this Healio Video Perspective from the ASCRS meeting, John D. Sheppard, MD, MMSc, FACS, discusses a post hoc analysis of two clinical trials investigating Miebo for the treatment of dry eye disease.

As Healio’s coverage of the American Society of Cataract and Refractive Surgery meeting continues, take a look at the most popular articles and videos so far.

BOSTON — In this Healio Video Perspective from the ASCRS meeting, Adam K. Muzychuk, MD, FRCSC, discusses findings that compared an “ultra-low” cylinder-powered 0.9 D toric IOL with a non-toric IOL after cataract surgery.

BOSTON — In this Healio Video Perspective from the ASCRS meeting, Kin Sheng Lim, MD, discusses a randomized controlled trial on endoscopic cyclophotocoagulation, or ECP, for primary open-angle glaucoma.

BOSTON — In this Healio Video Perspective from the ASCRS meeting, Richard A. Lewis, MD, chief medical officer of ViaLase, provides an update on femtosecond laser image-guided high-precision trabeculotomy for the treatment of glaucoma.

BOSTON — A sustained-release bimatoprost drug delivery platform shows promise in the treatment of ocular hypertension and open-angle glaucoma, according to a poster at the American Society of Cataract and Refractive Surgery meeting.

BOSTON — In this Healio Video Perspective from the ASCRS meeting, Darrell E. White, MD, discusses positive patient comfort results with Miebo from the phase 3 MOJAVE and GOBI trials.